VP R&DSend mail
A randomized, double-blind, placebo-controlled trial with Probi’s probiotic strains was shown to reduce gastrointestinal problems for women receiving pelvic radiotherapy.
The 3-armed study included 75 women with gynecological cancer receiving pelvic radiotherapy. The patients were either given a high or a low dose of the combined probiotic strains Lactiplantibacillus plantarum HEAL9 (HEAL9™) and Lactiplantibacillus plantarum 6595 or placebo. The study was conducted on two sites in Sweden.
When receiving radiotherapy in connection with gynecological cancer, women often experience gastrointestinal problems during and after the therapy. This study showed significantly reduced severity and frequency of both abdominal pain and defecation urgency.
The study “Decreasing the Adverse Effects in Pelvic Radiation Therapy: A Randomized Controlled Trial Evaluating the Use of Probiotics” was published in Advances in Radiation Oncology (2022)8, 101089.
Read the full publication here
News - 4 Jul 2022
Research within the area of microbiota and bone mass is a new and very promising area for probiotics. An exciting new study shows...Read news
Probi® has spent more than thirty years investigating the safety and efficacy of our probiotic strains. We conduct...Read more
News - 7 Dec 2021
A recent publication by McFarland and colleagues concludes that the probiotic strain LP299V® is one of the few probiotics which...Read news